Collij, Lyduine E. http://orcid.org/0000-0001-6263-1762
Mastenbroek, Sophie E.
Mattsson-Carlgren, Niklas
Strandberg, Olof
Smith, Ruben http://orcid.org/0000-0001-7147-0112
Janelidze, Shorena
Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Ossenkoppele, Rik http://orcid.org/0000-0003-1584-7477
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Article History
Received: 6 March 2024
Accepted: 3 September 2024
First Online: 14 September 2024
Competing interests
: L.E.C. has acquired research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly), both paid to institution. Dr. Collij’s salary is supported by the MSCA Postdoctoral fellowship (#101108819) and Alzheimer Association Research Fellowship (#23AARF-1029663) grants. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. R.O. has received research funding from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer’s fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden (all paid to the institutions). R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, and has given lectures in symposia sponsored by GE Healthcare. He is an advisory board member for Asceneuron and Bristol Myers Squibb. All the aforementioned has been paid to the institutions. He is an editorial board member of Alzheimer’s Research & Therapy and the European Journal of Nuclear Medicine and Molecular Imaging. S.P. has acquired research support (for the institution) from ki elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Lilly, and Roche. N.M.C. has received funding from WASP and DDLS Joint call for research projects (WASP/DDLS22-066), EU Join Program Neurodegenerative Diseases (2019-03401). The remaining authors declare no competing interests.